Pharmabiz10h
EMA committee recommends Novo Nordisk’s Wegovy label update to reflect reduced heart failure symptoms and improved physical function
Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST] ...
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Santé log23h
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was ...
STAT23h
Novo’s new obesity drug shows modest results, raises concerns of psychiatric side effects
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...
Investor's Business Daily on MSN23h
Novo Dives — And Corbus Crashes — On Psychiatric Side Effects Of Weight-Loss Drug
Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.